Human hepatocellular carcinomas with “Stemness”‐related marker expression: keratin 19 expression and a poor prognosis

Haeryoung Kim, Gi Hong Choi, Deuk Chae Na, Ei Young Ahn, Gwang Il Kim, Jae Eun Lee, Jai Young Cho, Jeong Eun Yoo, Jin Sub Choi, Young Nyun Park – 11 July 2011 – There is a recently proposed subtype of hepatocellular carcinoma (HCC) that is histologically similar to usual HCC, but characterized by the expression of “stemness”‐related markers. A large‐scale study on two different cohorts of HCCs was performed to investigate the clinicopathologic features and epithelial‐mesenchymal transition (EMT)‐related protein expression status of this subtype of HCCs.

Endothelial nitric oxide synthase is a key mediator of hepatocyte proliferation in response to partial hepatectomy in mice

Yu Mei, Sundararajah Thevananther – 11 July 2011 – Endothelial nitric oxide synthase (eNOS) is a critical modulator of vascular tone and blood flow and plays major roles in liver physiology and pathophysiology. Nitric oxide (NO) is widely recognized as one of the key humoral factors important for the initiation of liver regeneration in response to partial hepatectomy. Liver regeneration in response to partial hepatectomy is dependent on the efficiency of growth factor‐mediated cell‐cycle progression.

Conditional disruption of mouse HFE2 gene: Maintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hemojuvelin

Konstantinos Gkouvatsos, John Wagner, George Papanikolaou, Giada Sebastiani, Kostas Pantopoulos – 11 July 2011 – Mutations of the HFE2 gene are linked to juvenile hemochromatosis, a severe hereditary iron overload disease caused by chronic hyperabsorption of dietary iron. HFE2 encodes hemojuvelin (Hjv), a membrane‐associated bone morphogenetic protein (BMP) coreceptor that enhances expression of the liver‐derived iron regulatory hormone hepcidin. Hjv is primarily expressed in skeletal muscles and at lower levels in the heart and the liver.

Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations

Christoph Neumann‐Haefelin, Cesar Oniangue‐Ndza, Thomas Kuntzen, Julia Schmidt, Katja Nitschke, John Sidney, Célia Caillet‐Saguy, Marco Binder, Nadine Kersting, Michael W. Kemper, Karen A. Power, Susan Ingber, Laura L. Reyor, Kelsey Hills‐Evans, Arthur Y. Kim, Georg M. Lauer, Volker Lohmann, Alessandro Sette, Matthew R. Henn, Stéphane Bressanelli, Robert Thimme, Todd M. Allen – 11 July 2011 – Human leukocyte antigen B27 is associated with spontaneous viral clearance in hepatitis C virus (HCV) infection.

Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: A prospective, multicenter study

Shinji Tanaka, Kaoru Mogushi, Mahmut Yasen, Daisuke Ban, Norio Noguchi, Takumi Irie, Atsushi Kudo, Noriaki Nakamura, Hiroshi Tanaka, Masakazu Yamamoto, Norihiro Kokudo, Tadatoshi Takayama, Seiji Kawasaki, Michiie Sakamoto, Shigeki Arii – 11 July 2011 – The prediction of cancer recurrence holds the key to improvement of the postoperative prognosis of patients. In this study, the recurrence of early‐stage hepatocellular carcinoma (HCC) after curative hepatectomy was analyzed by the genome‐wide gene‐expression profiling on cancer tissue and the noncancerous liver tissue.

Retreatment with telaprevir combination therapy in hepatitis C patients with well‐characterized prior treatment response

Andrew J. Muir, Fred F. Poordad, John G. McHutchison, Mitchell L. Shiffman, Thomas Berg, Peter Ferenci, E. Jenny Heathcote, Jean‐Michel Pawlotsky, Stefan Zeuzem, Henk W. Reesink, Geoffrey Dusheiko, Emily C. Martin, Shelley George, Robert S. Kauffman, Nathalie Adda – 11 July 2011 – Retreatment with peginterferon alpha and ribavirin (PR) offers a limited chance of sustained virologic response (SVR) in patients who did not achieve SVR with prior PR treatment.

Subscribe to